Linked Life Data

3055672

Source:http://linkedlifedata.com/resource/pubmed/id/3055672

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1988-12-22
pubmed:abstractText
A randomized clinical study of adjuvant immunotherapy with decaris was carried out in patients with early breast cancer. 92 patients with stages I and IIA tumors (T1,2N0M0) received 300 mg decaris weekly (150 mg for 2 successive days) 2 weeks after radical mastectomy (Patey) used as a sole preventive therapy. The short (1 month) (group I), the medium (3 months) (group 2) and the long-term intermittent (three 3 month courses during 15 months) (group 3) modalities were compared. The prolonged intermittent course of decaris administration proved superior since it assured improvement in immunity and longer relapse-free survival, and lacked apparent toxicity. Five-year survival in all decaris treated patients was 93.8%, while five-year relapse-free course in group 3 was registered in 96.9%.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0507-3758
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1182-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
[Immunotherapy with decaris in the early stages of breast cancer].
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, English Abstract, Randomized Controlled Trial